These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11689679)

  • 1. Vaccination with attenuated simian immunodeficiency virus by DNA inoculation.
    Kent SJ; Dale CJ; Preiss S; Mills J; Campagna D; Purcell DF
    J Virol; 2001 Dec; 75(23):11930-4. PubMed ID: 11689679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectivity of wild-type and deleted proviral SIV DNA.
    Purcell DF; Cameron PU; Mills J; Kent S
    Dev Biol (Basel); 2001; 106():395-406. PubMed ID: 11761255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of recombination between 3' and 5' LTRs in macaques inoculated with SIV DNA.
    Kent SJ; Dale CJ; Preiss S; Purcell DF
    AIDS Res Hum Retroviruses; 2002 Feb; 18(3):227-30. PubMed ID: 11839158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased neurotropism of nef long terminal repeat (nef/LTR)-deleted simian immunodeficiency virus.
    Thompson KA; Kent SJ; Gahan ME; Purcell DF; McLean CA; Preiss S; Dale CJ; Wesselingh SL
    J Neurovirol; 2003 Aug; 9(4):442-51. PubMed ID: 12907389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys.
    Goletti D; Macchia I; Leone P; Pace M; Sernicola L; Pavone-Cossut MR; Maggiorella MT; Cafaro A; Ensoli B; Titti F
    Med Sci Monit; 2006 Oct; 12(10):BR330-40. PubMed ID: 17006396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuated and wild-type HIV-1 infections and long terminal repeat-mediated gene expression from plasmids delivered by gene gun to human skin ex vivo and macaques in vivo.
    Kent SJ; Cameron PU; Reece JC; Thompson PR; Purcell DF
    Virology; 2001 Aug; 287(1):71-8. PubMed ID: 11504543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge.
    Michelini Z; Negri DR; Baroncelli S; Catone S; Comini A; Maggiorella MT; Sernicola L; Crostarosa F; Belli R; Mancini MG; Farcomeni S; Fagrouch Z; Ciccozzi M; Rovetto C; Liljestrom P; Norley S; Heeney J; Titti F
    J Med Primatol; 2004 Oct; 33(5-6):251-61. PubMed ID: 15525326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccine protection against challenge with simian/human immunodeficiency virus 89.6 in rhesus macaques.
    Habel A; Chanel C; Le Grand R; Martinon F; Couillin L; Moog C; Doms R; Gauduin MC; Hurtrel B; Guillet JG; Aubertin AM; Girard M
    Dev Biol (Basel); 2000; 104():101-5. PubMed ID: 11713807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
    McKenna PM; Koser ML; Carlson KR; Montefiori DC; Letvin NL; Papaneri AB; Pomerantz RJ; Dietzschold B; Silvera P; McGettigan JP; Schnell MJ
    J Infect Dis; 2007 Apr; 195(7):980-8. PubMed ID: 17330788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
    Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
    Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism for the establishment of transcriptional HIV latency in the brain in a simian immunodeficiency virus-macaque model.
    Barber SA; Gama L; Dudaronek JM; Voelker T; Tarwater PM; Clements JE
    J Infect Dis; 2006 Apr; 193(7):963-70. PubMed ID: 16518758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques.
    Schulte R; Suh YS; Sauermann U; Ochieng W; Sopper S; Kim KS; Ahn SS; Park KS; Stolte-Leeb N; Hunsmann G; Sung YC; Stahl-Hennig C
    Virology; 2009 Jan; 383(2):300-9. PubMed ID: 19027133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhesus macaques with high levels of vaccine induced IFN-gamma producing cells better control viral set-point following challenge with SIV239.
    Boyer JD; Maciag PC; Parkinson R; Wu L; Lewis MG; Weiner DB; Paterson Y
    Vaccine; 2006 May; 24(21):4498-502. PubMed ID: 16185790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversion in vivo after inoculation of a molecular proviral DNA clone of simian immunodeficiency virus with a cytotoxic-T-lymphocyte escape mutation.
    Kobayashi M; Igarashi H; Takeda A; Kato M; Matano T
    J Virol; 2005 Sep; 79(17):11529-32. PubMed ID: 16103206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.
    Johnson PR; Montefiori DC; Goldstein S; Hamm TE; Zhou J; Kitov S; Haigwood NL; Misher L; London WT; Gerin JL
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2175-9. PubMed ID: 1549578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon.
    Giavedoni LD; Yilma T
    J Virol; 1996 Apr; 70(4):2247-51. PubMed ID: 8642649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.